Skip to main content
Media Hub

News

  • Corporate

    World Prematurity Day: Chiesi for preterm babies

    November 17 th it’s the World Prematurity Day (WPD). The WPD aims at raising awareness of the challenges of preterm birth globally, one of the largest cause of perinatal and neonatal mortality and morbidity in children (source: World Health Organization). Without an appropriate treatment, the babies…

  • Corporate

    FDA approves Bronchitol (mannitol) for cystic fibrosis

    Bronchitol® indicated as add-on maintenance therapy to improve pulmonary function in adult patients with cystic fibrosis (CF) CARY, NORTH CAROLINA, NOVEMBER 02, 2020 – Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi…

  • Corporate

    Regeneration 20|30 programme launches in Parma

    The 20|30 temporal frontier is essential: we have no more than 10 years to give a concrete response to the problem of the climate change, while working on a new regenerative model that puts social equality, happiness and well-being of individuals at the center of the strategy, as well as economic…

  • Corporate

    Chiesi joins the Italy for Climate initiative

    Making the climate the pivot of the strategy for economic and employment recovery: this is the objective of Italy for Climate, the initiative promoted by the Fondazione per lo Sviluppo Sostenibile and a virtuous group of companies (Conou, Davines, e2i, ERG, illy, ING), including Chiesi Group, with…

  • Corporate

    Chiesi joins the B Corp Unlock The Change campaign

    The Chiesi Group is pleased to take part in the “Unlock The Change” campaign, the awareness-raising project launched by the B Corp community, together with Nativa, one of the leading companies of the movement in Italy. The initiative has been launched last Thursday, July 16 th during the B Corp…

  • Corporate

    The B Change: Pharmastar's B Corp instant book

    The Instant Book "Doing business today is also an environmental and social value. The B Change" is online. It has been edited by the editorial staff of Pharmastar and it is dedicated to the international movement of the B Corps. This document is intended to provide a detailed overview of the B Corp…

  • Corporate

    Holoclar transferred from Chiesi to Holostem

    Chiesi Farmaceutici, international research-focussed group (Chiesi Group), and Holostem Terapie Avanzate, top Italian biotech company entirely dedicated to the development, production, registration and distribution of medicinal products for advanced therapies, announce the signing of a contract for…

  • Corporate

    Maria Paola Chiesi at the Vatican wellbeing workshop

    The Covid-19 pandemic has been certainly an opportunity to reflect on the lifestyle of our society and on the future of the new generations. Alongside the health crisis, however, on the path to our “normal” life, the risk is to forget other equally important crises, such as the social and climate…

  • Corporate

    Protalix and Chiesi submit PRX-102 BLA for Fabry

    CARMIEL, Israel, May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein…